Iranian
Biomedical Journal
Volume 29, Issue 6 (11-2025)
IBJ 2025, 29(6): 405-412 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mashayekhi P, Omrani* M D, Dehghanifard A, Khosravi A, Jahani M M, Khosravi N. Liquid Biopsy for EGFR Mutation Detection in NSCLC: Evaluation of Plasma ctDNA and Comparison with Plasma exoDNA. IBJ 2025; 29 (6) :405-412
URL: http://ibj.pasteur.ac.ir/article-1-4700-en.html
URL: http://ibj.pasteur.ac.ir/article-1-4700-en.html
Parisa Mashayekhi * 
, Mir Davood Omrani* , Ali Dehghanifard , Adnan Khosravi , Mohammad Mehdi Jahani , Negin Khosravi
, Mir Davood Omrani* , Ali Dehghanifard , Adnan Khosravi , Mohammad Mehdi Jahani , Negin Khosravi
Abstract:
Background: Accurate detection of actionable EGFR mutations is essential for guiding targeted therapy in NSCLC. Liquid biopsy approaches using ctDNA and exoDNA offer noninvasive alternatives for molecular profiling. This study evaluated the diagnostic performance of nested PCR combined with sanger sequencing for detecting common EGFR mutations (exon 19 deletions and the L858R point mutation) in plasma samples from Iranian NSCLC patients.
Methods: In this retrospective observational study, blood samples were collected from 30 NSCLC patients with confirmed EGFR mutations. ctDNA was extracted from plasma and analyzed using nested PCR followed by sanger sequencing. Specificity was assessed in 20 EGFR–wild‑type NSCLC patients serving as controls. Diagnostic performance was further evaluated in relation to clinicopathological factors.
Results: EGFR mutations were detected in plasma ctDNA in 63.3% of patients. Detection sensitivity was significantly associated with tumor stage but was independent of mutation subtype, age, sex, or smoking status. The assay showed high specificity, with no false‑positive results in control samples (95% CI: 83.9–100.0%). Although exoDNA analysis demonstrated a higher sensitivity than ctDNA (76.6% vs. 63.3%), this difference was not statistically significant. Notably, combined analysis of ctDNA and exoDNA increased overall detection sensitivity to 80%.
Conclusions: Nested PCR with sanger sequencing represents a reliable rule‑in strategy for EGFR mutation detection in plasma. Integrating ctDNA and exoDNA analyses substantially improves sensitivity and may enhance noninvasive molecular diagnostics in NSCLC.
Methods: In this retrospective observational study, blood samples were collected from 30 NSCLC patients with confirmed EGFR mutations. ctDNA was extracted from plasma and analyzed using nested PCR followed by sanger sequencing. Specificity was assessed in 20 EGFR–wild‑type NSCLC patients serving as controls. Diagnostic performance was further evaluated in relation to clinicopathological factors.
Results: EGFR mutations were detected in plasma ctDNA in 63.3% of patients. Detection sensitivity was significantly associated with tumor stage but was independent of mutation subtype, age, sex, or smoking status. The assay showed high specificity, with no false‑positive results in control samples (95% CI: 83.9–100.0%). Although exoDNA analysis demonstrated a higher sensitivity than ctDNA (76.6% vs. 63.3%), this difference was not statistically significant. Notably, combined analysis of ctDNA and exoDNA increased overall detection sensitivity to 80%.
Conclusions: Nested PCR with sanger sequencing represents a reliable rule‑in strategy for EGFR mutation detection in plasma. Integrating ctDNA and exoDNA analyses substantially improves sensitivity and may enhance noninvasive molecular diagnostics in NSCLC.
Type of Study: Full Length/Original Article |
Subject:
Cancer Biology
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |